Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Toshkov

Showing results (111-120 of 119) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 119 results.
Cell Cycle (Georgetown, Tex.)|April 21, 2010
A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in miceKaterina I Leonova, Jelena Shneyder, Marina P Antoch, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2005
Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucksJohn Casey, Paul J Cote, Illia A Toshkov, et al.
Hepatology (Baltimore, Md.)|April 2, 2004
Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumorsJames R Jacob, Agnes Sterczer, Ilia A Toshkov, et al.
Oncotarget|March 4, 2014
Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in miceBojidar M Kojouharov, Craig M Brackett, Jean M Veith, et al.
Gastroenterology|October 28, 2004
Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infectionBud C Tennant, Ilia A Toshkov, Simon F Peek, et al.
Hepatology (Baltimore, Md.)|December 22, 2000
Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax)S F Peek, P J Cote, J R Jacob, et al.
Plos One|September 15, 2015
The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human PrimatesVadim I Krivokrysenko, Ilia A Toshkov, Anatoli S Gleiberman, et al.
Communications Biology|April 13, 2021
A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applicationsVadim Mett, Oleg V Kurnasov, Ivan A Bespalov, et al.
Oncogene|October 3, 2017
Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapyV Mett, E A Komarova, K Greene, et al.
Pageof 12

Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Cell Cycle (Georgetown, Tex.)|April 21, 2010
A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in miceKaterina I Leonova, Jelena Shneyder, Marina P Antoch, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2005
Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucksJohn Casey, Paul J Cote, Illia A Toshkov, et al.
Hepatology (Baltimore, Md.)|April 2, 2004
Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumorsJames R Jacob, Agnes Sterczer, Ilia A Toshkov, et al.
Oncotarget|March 4, 2014
Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in miceBojidar M Kojouharov, Craig M Brackett, Jean M Veith, et al.
Gastroenterology|October 28, 2004
Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infectionBud C Tennant, Ilia A Toshkov, Simon F Peek, et al.
Hepatology (Baltimore, Md.)|December 22, 2000
Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax)S F Peek, P J Cote, J R Jacob, et al.
Plos One|September 15, 2015
The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human PrimatesVadim I Krivokrysenko, Ilia A Toshkov, Anatoli S Gleiberman, et al.
Communications Biology|April 13, 2021
A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applicationsVadim Mett, Oleg V Kurnasov, Ivan A Bespalov, et al.
Oncogene|October 3, 2017
Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapyV Mett, E A Komarova, K Greene, et al.
Pageof 12